Sign in

    Greg Silvaniouve • Mizuho Financial Group

    No publicly verifiable information about Greg Silvaniouve as an analyst at Mizuho Financial Group can be found in available records or professional directories. There is no evidence of this individual holding an analyst or research position at Mizuho, nor are there any performance metrics, coverage specialties, or past career details listed in authoritative industry sources or the firm's official people directory. As a result, there is no basis to detail professional credentials, specific company coverage, or notable achievements for this persona.

    Greg Silvaniouve's questions to EyePoint Pharmaceuticals Inc (EYPT) leadership

    Greg Silvaniouve's questions to EyePoint Pharmaceuticals Inc (EYPT) leadership • Q2 2025

    Question

    Speaking on behalf of Greg Silvaniouve, an analyst from Mizuho asked about the physician feedback on DuraVu at the recent ASRS meeting and what incremental data to expect from the upcoming VORONA end-of-study presentation.

    Answer

    CEO Dr. Jay Duker described the ASRS feedback as 'incredibly positive,' with physicians excited about DuraVu's new mechanism of action and potential for six-month durability. CMO Dr. Ramiro Ribeiro added that the September VORONA presentation will build upon previously released data regarding BCVA, CST, and treatment burden reduction.

    Ask Fintool Equity Research AI